NSE: ZYDUSLIFE · 13 October 2026 · Pre-market update
- Zydus Lifesciences is in focus ahead of the market open following a presentation by its subsidiary, Zydus Therapeutics, regarding a new post hoc analysis of the Phase 3 EPICS-III trial for saroglitazar in primary biliary cholangitis (PBC) at the ACG 2026 Annual Meeting. The investigative drug is currently under review by the U.S. FDA, with a planned launch by March 2027 if approved.
- Zydus Therapeutics shared a post hoc exploratory analysis of geographic subgroups from the pivotal EPICS-III trial at the American College of Gastroenterology 2026 Annual Meeting. The results showed a numerically higher biochemical response treatment difference in the U.S. subgroup compared to the non-U.S. subgroup in adult patients with primary biliary cholangitis who had inadequate response or intolerance to ursodeoxycholic acid.
- Trading volume was 0.33 times the 20-day average daily volume.
Zydus Lifesciences Company News Before Market Open
Zydus Lifesciences is in focus ahead of the market open following a presentation by its subsidiary, Zydus Therapeutics, regarding a new post hoc analysis of the Phase 3 EPICS-III trial for saroglitazar in primary biliary cholangitis (PBC) at the ACG 2026 Annual Meeting. The investigative drug is currently under review by the U.S. FDA, with a planned launch by March 2027 if approved.
5.30 lakh shares traded on 9 October 2026. This compares with a 20-day average daily volume of 15.99 lakh shares (0.33 times). The five-day average daily volume was 17.21 lakh shares.
Saroglitazar is currently under review by the U.S. FDA for the treatment of primary biliary cholangitis with a potential commercial launch targeted for March 2027. The newly presented exploratory subgroup data from the Phase 3 EPICS-III trial highlights regional biochemical response rates in patients with limited treatment options. Zydus Lifesciences closed the previous trading session on October 9, 2026, at ₹1,117.50, up 0.49%, ahead of this clinical disclosure.
Latest Company Developments
Zydus Therapeutics shared a post hoc exploratory analysis of geographic subgroups from the pivotal EPICS-III trial at the American College of Gastroenterology 2026 Annual Meeting. The results showed a numerically higher biochemical response treatment difference in the U.S. subgroup compared to the non-U.S. subgroup in adult patients with primary biliary cholangitis who had inadequate response or intolerance to ursodeoxycholic acid.
Provides deeper clinical insights into the efficacy profile of saroglitazar across regional populations as the drug undergoes U.S. FDA regulatory review.
a press release dated October 12, 2026, titled "Zydus Therapeutics Presents New Post Hoc Analysis of Phase 3 EPICS-III Trial at ACG 2026 Showing Greater Biochemical Response With Investigational Saroglitazar Compared to Placebo Across Geographic Subgroups in PBC".
Ownership & Transaction Activity
Mutual Fund Holdings
Mutual funds held 6.88% on 30 September 2026. This compares with 5.12% on 30 June 2026, a change of +1.76 percentage points.
The filing reported 41 MF/UTI holders.
What to Watch Next
- Trading volume and investor participation in Zydus Lifesciences cash market shares at the open following the clinical data presentation.
- Any further updates regarding the ongoing U.S. FDA regulatory review timeline for saroglitazar.
- Price action relative to the prior session range of ₹1,105.40 to ₹1,123.70 and the 20-day average close of ₹1,151.02.
Other Dated Coverage
- Zydus Lifesciences Share Price Today: Why ZYDUSLIFE Is Falling 0.56% | 7 October 2026 — 7 October 2026
- Why Zydus Life Shares Are Rising 1.80% Today | 6 October 2026 — 6 October 2026
- Why Zydus Lifesciences Shares Fell 2.46% Today: Market Context | 1 October 2026 — 1 October 2026
More Zydus Lifesciences news and dated analysis →
Frequently Asked Questions
What is the latest Zydus Lifesciences company news?
Zydus Therapeutics shared a post hoc exploratory analysis of geographic subgroups from the pivotal EPICS-III trial at the American College of Gastroenterology 2026 Annual Meeting. The results showed a numerically higher biochemical response treatment difference in the U.S. subgroup compared to the non-U.S. subgroup in adult patients with primary biliary cholangitis who had inadequate response or intolerance to ursodeoxycholic acid.
How strong was Zydus Lifesciences’s trading volume?
5.30 lakh shares traded, 0.33 times the 20-day average daily volume. The price and volume data are dated 9 October 2026.
Do the mutual-fund figures show buying today?
They show holdings on 30 September 2026. Quarterly holdings do not identify purchases made on the article date.
Research & analysis: WittyTrades Research Desk
Reviewed by: Mohanish Sanghavi — SEBI Registered Research Analyst
Disclaimer: Investments in securities markets are subject to market risks. Registration with SEBI and NISM certification do not guarantee performance or returns. This article is for information and education, not personalised investment advice or a recommendation to buy, sell or hold.